CN104394868A - 嘌呤类似物的环丙烷羧酸酯 - Google Patents

嘌呤类似物的环丙烷羧酸酯 Download PDF

Info

Publication number
CN104394868A
CN104394868A CN201380032742.6A CN201380032742A CN104394868A CN 104394868 A CN104394868 A CN 104394868A CN 201380032742 A CN201380032742 A CN 201380032742A CN 104394868 A CN104394868 A CN 104394868A
Authority
CN
China
Prior art keywords
compound
amido
alkyl
hydrogen
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380032742.6A
Other languages
English (en)
Chinese (zh)
Inventor
陈基旺
赖信羽
张佩德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricky Biotechnology New Pharmaceutical Co ltd
Original Assignee
Annji Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharmaceutical Co Ltd filed Critical Annji Pharmaceutical Co Ltd
Publication of CN104394868A publication Critical patent/CN104394868A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CN201380032742.6A 2012-04-20 2013-04-02 嘌呤类似物的环丙烷羧酸酯 Pending CN104394868A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261635931P 2012-04-20 2012-04-20
US61/635,931 2012-04-20
PCT/US2013/035042 WO2013158367A1 (en) 2012-04-20 2013-04-02 Cyclopropanecarboxylate esters of purine analogues

Publications (1)

Publication Number Publication Date
CN104394868A true CN104394868A (zh) 2015-03-04

Family

ID=49380678

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380032742.6A Pending CN104394868A (zh) 2012-04-20 2013-04-02 嘌呤类似物的环丙烷羧酸酯
CN201380020494.3A Expired - Fee Related CN104302287B (zh) 2012-04-20 2013-04-03 作为蛋白质激酶抑制剂的吲哚啉‑2‑酮衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380020494.3A Expired - Fee Related CN104302287B (zh) 2012-04-20 2013-04-03 作为蛋白质激酶抑制剂的吲哚啉‑2‑酮衍生物

Country Status (13)

Country Link
US (2) US8969361B2 (enExample)
EP (2) EP2838538B1 (enExample)
JP (2) JP6177879B2 (enExample)
KR (2) KR101774861B1 (enExample)
CN (2) CN104394868A (enExample)
AU (2) AU2013249708B2 (enExample)
BR (1) BR112014026182A2 (enExample)
ES (2) ES2621257T3 (enExample)
IL (2) IL235097A (enExample)
IN (2) IN2014MN02105A (enExample)
RU (2) RU2642463C2 (enExample)
TW (2) TWI496784B (enExample)
WO (2) WO2013158367A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113307799A (zh) * 2021-05-21 2021-08-27 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
CN114380802A (zh) * 2022-01-07 2022-04-22 贵州大学 一类含咔唑基咪唑盐类化合物及其制备方法和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
CR20180255A (es) 2015-11-06 2018-06-22 Hoffmann La Roche Derivados de indolin-2-ona
CN106831707B (zh) * 2016-12-28 2019-09-20 杭州市西溪医院 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
EP4267642A1 (de) 2020-12-23 2023-11-01 Basf Se Neuer katalysator zur herstellung von polyurethanen
CN113999221B (zh) * 2021-11-04 2024-04-05 南京中医药大学 6-位取代的吲哚酮衍生物及其医药用途
EP4623016A1 (de) 2022-11-24 2025-10-01 Basf Se Verbesserung der lagerstabilität von hydrofluorolefinen in aminhaltigen polyolkomponenten für die herstellung von polyurethanen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102083437A (zh) * 2008-03-07 2011-06-01 雷·W·埃克斯利 疱疹病毒相关疾病的治疗

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT351865B (de) 1977-04-01 1979-08-27 Hoffmann La Roche Akarizide mittel
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
CO5031249A1 (es) * 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
ATE369359T1 (de) 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
WO2005040116A2 (en) 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
WO2006127217A2 (en) * 2005-05-25 2006-11-30 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
JP2009508971A (ja) 2005-09-22 2009-03-05 ザ スクリプス リサーチ インスティテュート アルコキシインドリノン系プロテインキナーゼ阻害剤
CN1850794A (zh) * 2006-05-30 2006-10-25 中国医学科学院医药生物技术研究所 3－酰胺基取代苯甲酰脲类化合物及其抗肿瘤作用
CA2672101A1 (en) 2006-12-11 2008-06-19 Irm Llc Compounds and compositions as kinase inhibitors
PL2101733T3 (pl) * 2006-12-13 2013-02-28 Hoffmann La Roche Preparat w postaci proszku walgancyklowiru
US20100184747A1 (en) 2007-06-12 2010-07-22 Boehringer Ingelheim International Gmbh Indoline derivatives and their use in treating disease-states such as cancer
US7846793B2 (en) 2007-10-03 2010-12-07 Applied Materials, Inc. Plasma surface treatment for SI and metal nanocrystal nucleation
EP2274311A2 (en) * 2008-03-28 2011-01-19 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Compounds and methods for the treatment of viral infection
UY31929A (es) * 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
RU2011103189A (ru) * 2008-06-30 2012-08-10 Силин Фармасьютикалз, Инк. (Us) Производные оксиндола
US20100298376A1 (en) * 2009-05-13 2010-11-25 Board Of Regents, The University Of Texas System Use of novel neuroprotective 3-substituted indolone compositions
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
JP5909495B2 (ja) * 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102083437A (zh) * 2008-03-07 2011-06-01 雷·W·埃克斯利 疱疹病毒相关疾病的治疗

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113307799A (zh) * 2021-05-21 2021-08-27 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
CN114380802A (zh) * 2022-01-07 2022-04-22 贵州大学 一类含咔唑基咪唑盐类化合物及其制备方法和应用
CN114380802B (zh) * 2022-01-07 2023-11-17 贵州大学 一类含咔唑基咪唑盐类化合物及其制备方法和应用

Also Published As

Publication number Publication date
IL235097A (en) 2017-07-31
KR101774861B1 (ko) 2017-09-05
WO2013158373A1 (en) 2013-10-24
JP6177879B2 (ja) 2017-08-09
WO2013158367A1 (en) 2013-10-24
EP2838538A1 (en) 2015-02-25
TWI496784B (zh) 2015-08-21
US8946282B2 (en) 2015-02-03
KR101778095B1 (ko) 2017-09-13
IN2014MN02107A (enExample) 2015-09-11
TW201350485A (zh) 2013-12-16
RU2014145480A (ru) 2016-06-10
US20130281517A1 (en) 2013-10-24
JP2015514762A (ja) 2015-05-21
US20130281451A1 (en) 2013-10-24
CN104302287A (zh) 2015-01-21
RU2014145481A (ru) 2016-06-10
RU2627706C2 (ru) 2017-08-10
BR112014026182A2 (pt) 2017-06-27
IN2014MN02105A (enExample) 2015-09-11
KR20150005630A (ko) 2015-01-14
AU2013249714B2 (en) 2016-12-15
EP2838531A4 (en) 2015-12-16
AU2013249708A1 (en) 2014-11-13
ES2621257T3 (es) 2017-07-03
EP2838531A1 (en) 2015-02-25
TW201343627A (zh) 2013-11-01
KR20150005600A (ko) 2015-01-14
AU2013249708B2 (en) 2017-03-16
CN104302287B (zh) 2017-12-26
IL235098A0 (en) 2014-12-31
WO2013158373A8 (en) 2014-10-30
RU2642463C2 (ru) 2018-01-25
US8969361B2 (en) 2015-03-03
EP2838538B1 (en) 2017-03-15
ES2600467T3 (es) 2017-02-09
JP6174119B2 (ja) 2017-08-02
AU2013249714A1 (en) 2014-11-13
EP2838538A4 (en) 2015-09-02
EP2838531B1 (en) 2016-09-21
JP2015514761A (ja) 2015-05-21
TWI458709B (zh) 2014-11-01

Similar Documents

Publication Publication Date Title
CN104394868A (zh) 嘌呤类似物的环丙烷羧酸酯
CN109311854B (zh) 具有仲酰胺官能团的苯并氮杂卓二甲酰胺化合物
CN109311851B (zh) 二氢嘧啶基苯并氮杂䓬甲酰胺化合物
US9890124B2 (en) Benzazepine sulfonamide compounds
CN1938307B (zh) 9-取代的8-氧代腺嘌呤
US10993943B2 (en) Crystalline forms of selinexor and process for their preparation
ES2765805T3 (es) Inhibidores de kinurenina-3-monoxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
PH12015500758B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BRPI0611435A2 (pt) derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
SA95160158B1 (ar) مشتقات 2-(2- أمينو-6.1- ثنائي هيدرو -6- أوكسو – بيورين -9- يل) ميثوكسي -3.1-بروبان دايول 2-(2-amino-1.6-dihydro-oxo-purin-9-y1)methoxy-1.3-propanediol
US20200369652A1 (en) Processes for preparation of lifitegrast and intermediates thereof
KR20200108828A (ko) 발베나진의 고상 형태
US20100197732A1 (en) Repaglinide Substantially Free of Dimer Impurity
CN114805478A (zh) 氘代拟肽类化合物及其用途
AU2020255702B2 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
WO2013192610A2 (en) Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
EP1992622A1 (en) 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
CN113880772A (zh) 一类cdk激酶抑制剂及其应用
WO2020098710A1 (zh) 一种取代的双芳香基酰胺化合物及其制备方法和应用
CN116514902A (zh) 氘代拟肽类化合物及其用途
CN115210244B (zh) 一种弹性蛋白酶抑制剂前药及其用途
WO2003095435A1 (en) Amide derivatives
HK40003986A (en) Benzazepine dicarboxamide compounds with secondary amide function
HK40003985A (en) Dihydropyrimidinyl benzazepine carboxamide compounds
HK1243701B (zh) 苯并氮杂䓬磺酰胺化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: Ai Road four Taipei City, Taiwan Chinese Daan District 25 1 Building No. 5

Applicant after: ANNJI PHARMACEUTICAL Co.,Ltd.

Address before: 2, building 12, 1 Guangfu Road South, Songshan District, Taipei, Taiwan, China

Applicant before: Ricky Biotechnology New Pharmaceutical Co.,Ltd.

Address after: Ai Road four Taipei City, Taiwan Chinese Daan District 25 1 Building No. 5

Applicant after: ANNJI PHARMACEUTICAL Co.,Ltd.

Address before: 2, building 12, 1 Guangfu Road South, Songshan District, Taipei, Taiwan, China

Applicant before: ANNJI PHARMACEUTICAL Co.,Ltd.

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160630

Address after: 2, building 12, 1 Guangfu Road South, Songshan District, Taipei, Taiwan, China

Applicant after: Ricky Biotechnology New Pharmaceutical Co.,Ltd.

Address before: Ai Road four Taipei City, Taiwan Chinese Daan District 25 1 Building No. 5

Applicant before: ANNJI PHARMACEUTICAL Co.,Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150304